Sarepta Therapeutics Stock Analysis (NASDAQ:SRPT)

Add to My Stocks
$28.68 $0.4 (1.41%) SRPT stock closing price Feb 21, 2017 (Closing)
Watch Robo Advisor Video of SRPT Stock Analysis
Sarepta Therapeutics
Updated on : Feb 21, 2017
previous close
SRPT 28.7 (0%)
S&P 500 2365.4 (0%)
Closing Price On: Feb 21, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Sector :
5 Quarter Revenue
Revenue Growth
Compared to the industry
Long Term Growth
5 Year CAGR:
5 Quarter Net Profit
Net Margins
LTM Margin
Debt/Equity Ratio
Debt/Equity Ratio:
Compared to the industry
Cash Flow
Operating cash flow:
Net Income:
Low Debt Burden
Recent Growth
Long Term Growth
Net Margins
Rating: ★★★★★★★★★★ (0/5)
Other Metrics
Return on Equity:
Double Tap To Exit Full Screen

Sarepta Therapeutics Analysis Video

131 5 2

View Sarepta Therapeutics stock analysis video. This is our SRPT analyst opinion covering the buy and sell arguments for SRPT stock.

Sarepta Therapeutics Inc Stock Rating (1.3/5)

Our Sarepta Therapeutics stock opinion is based on fundamentals of the company. This Sarepta Therapeutics stock analysis is based on latest Q3 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy SRPT stock?

  • With a debt/equity ratio of  0.05, Sarepta Therapeutics is comparatively less leveraged than its peers in the Medical sector.

Should you sell SRPT stock?

  • Sarepta Therapeutics sales declined by -999% year on year in 2016 Q3.
  • The company saw an average annual sales decline of in sales over the last 5 years.
  • Over the last 12 months, Sarepta Therapeutics had an average Net loss of -19479.2%.
  • Sarepta Therapeutics has a negative ROE (Return On Equity) of -113.1%, indicating the company is not profitable.

Comments on this video and Sarepta Therapeutics stock